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Structure of the DOCK2−ELMO1 complex provides
insights into regulation of the auto-inhibited state
Leifu Chang1,7, Jing Yang1, Chang Hwa Jo 2, Andreas Boland 1,8, Ziguo Zhang 1, Stephen H. McLaughlin 1,
Afnan Abu-Thuraia 3, Ryan C. Killoran2, Matthew J. Smith 2,4,9, Jean-Francois Côté 3,5,6,9 &
David Barford 1✉
DOCK (dedicator of cytokinesis) proteins are multidomain guanine nucleotide exchange
factors (GEFs) for RHO GTPases that regulate intracellular actin dynamics. DOCK proteins
share catalytic (DOCKDHR2) and membrane-associated (DOCKDHR1) domains. The
structurally-related DOCK1 and DOCK2 GEFs are specific for RAC, and require ELMO
(engulfment and cell motility) proteins for function. The N-terminal RAS-binding domain
(RBD) of ELMO (ELMORBD) interacts with RHOG to modulate DOCK1/2 activity. Here, we
determine the cryo-EM structures of DOCK2−ELMO1 alone, and as a ternary complex with
RAC1, together with the crystal structure of a RHOG−ELMO2RBD complex. The binary
DOCK2−ELMO1 complex adopts a closed, auto-inhibited conformation. Relief of auto-
inhibition to an active, open state, due to a conformational change of the ELMO1 subunit,
exposes binding sites for RAC1 on DOCK2DHR2, and RHOG and BAI GPCRs on ELMO1. Our
structure explains how up-stream effectors, including DOCK2 and ELMO1 phosphorylation,
destabilise the auto-inhibited state to promote an active GEF.
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RHO family small GTPases are critical regulators of cellmotility, polarity, adhesion, cytoskeletal organization,proliferation, gene expression and apoptosis. These diverse
functions are stimulated by the active GTP-bound state of RHO
proteins that engage a diverse array of effector proteins, thereby
triggering down-stream signal transduction pathways1,2. Con-
version of these biomolecular switches to the GTP-bound state is
controlled by two families of guanine nucleotide exchange factors
(GEFs); the Dbl family and the DOCK family3–6. GEFs catalyse
the release of bound GDP in exchange for GTP.
Dbl family proteins are a large group of RHO GEFs comprising a
catalytic Dbl homology (DH) domain with an adjacent PH domain,
within the context of functionally diverse signalling modules. The
evolutionary distinct and smaller family of DOCK proteins activates
CDC42 and RAC to control cell migration, morphogenesis and
phagocytosis, and have been implicated as important components
of tumour cell movement and invasion7–11. DOCK proteins exhibit
high specificity, in contrast to the Dbl GEFs that often stimulate
nucleotide exchange on multiple GTPases in vitro. In humans, the
eleven DOCK proteins are organized into four subfamilies encoding
multidomain proteins of ~2000 amino acids7,10. DOCK A
(DOCK1/DOCK180, DOCK2 and DOCK5) and DOCK B
(DOCK3 and DOCK4) subfamilies activate RAC, whereas the
DOCK D subfamily (DOCK9/Zizimin1, DOCK10 and DOCK11)
activates CDC4212–15, with only DOCK10 also activating RAC16.
DOCK6 and DOCK7 of the DOCK C (DOCK6, DOCK7 and
DOCK8) subfamily are dual specificity GEFs with activity towards
both RAC and CDC42 in vivo17–19, a finding recently confirmed
for DOCK7 in vitro20, whereas DOCK8 was shown to be a CDC42
GEF21.
All DOCK proteins contain a catalytic DHR2 domain of ~450
residues situated within their C-terminal region (DOCKDHR2)13,15
(Fig. 1a). The DHR2 domain is divergent across the family, with
the DHR2 domains of DOCK1 (RAC specific) and DOCK9
(CDC42 specific) sharing only 22% sequence identity13,15. A
second region of common similarity is the ~200 residue DHR1
domain located towards the N-terminus (DOCKDHR1) (Fig. 1a).
The DHR1 domain of DOCK proteins adopts a C2-like
a
b c
Fig. 1 Overall structure of the DOCK2−ELMO1−RAC1 complex. a Schematic of the domain structures of DOCK2, ELMO1 and RAC1. b, c Two views of the
cryo-EM map of the DOCK2−ELMO1−RAC1 complex with each domain colour-coded. Ribbon representation of the structural models were placed in the
cryo-EM density map. The two DOCK2−ELMO1−RAC1 protomers of the dimeric complex are indicated by light blue and light yellow backgrounds. The
open-conformation of the DOCK2−ELMO1−RAC1 complex is shown.
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architecture and interacts with PI(3,4,5)P3 to mediate signalling
and membrane localization22,23. DOCK proteins locate primarily
to the cytosol, but recruitment to the cell membrane is critical for
their roles in cytoskeleton reorganization24–26. DOCK A and B
subfamilies incorporate an N-terminal SH3 domain and an
extreme C-terminal poly-proline sequence (Fig. 1a). In contrast,
the DOCK D subfamily incorporates an N-terminal PH domain,
whereas the DOCK C subfamily lacks recognizable SH3 or PH
domains.
Stimulation of RAC-induced cytoskeletal reorganization by the
DOCK A and B subfamilies is dependent on interactions with
ELMO proteins26–29. The SH3 domain and neighbouring α-helical
region of the DOCK A and B subfamilies mediate their interactions
with ELMO subunits30,31. ELMO proteins comprise an N-terminal
domain (ELMONTD), a non-canonical PH domain (ELMOPH), and
a C-terminal poly-proline sequence (Fig. 1a). ELMONTD itself is
composed of an N-terminal RAS-binding domain (ELMORBD),
EID and ELMO domains (ELMOEID and ELMOELMO) (Fig. 1a).
Disruption of DOCK1−ELMO interactions abrogated DOCK1’s
ability to promote RAC-dependent cytoskeletal changes. Compared
with DOCK1 alone, the DOCK1−ELMO complex binds to
nucleotide-free RAC more efficiently and shows higher GEF
activity12,26–28.
Among DOCK proteins, DOCK2 plays multiple roles in reg-
ulating immune responses32. It is a haematopoietic cell protein
which functions downstream of chemokine receptors to control
actin reorganization, thus, regulating lymphocyte activation,
migration, and morphology32,33. In T cells DOCK2 acts down-
stream of the T cell receptor, and recently DOCK2 was implicated
in mediating signalling from the FLT3 protein tyrosine kinase
and identified as a leukaemia drug target32,33. Through binding to
the C-terminal polybasic region of DOCK2, phosphatidic acid
stabilizes the recruitment of DOCK2 to the cell membrane to
mediate neutrophil chemotaxis34.
In vivo, RHOG−GTP interacts with ELMO1RBD, an interac-
tion that is required for DOCK1-mediated RAC1 activation35,36.
Furthermore, the Arl family GTPase Arl4A promotes actin
cytoskeleton remodelling, dependent on ELMO1RBD, acting as a
membrane localization signal for ELMO137. The adhesion-type
BAI (brain-specific angiogenesis inhibitor) subfamily of GPCRs
are up-stream regulators of the DOCK−ELMO−RAC signalling
module, controlling engulfment and degradation of apoptotic
cells by phagocytes38, and promoting myoblast fusion39,40. BAI
receptors bind ELMO through their conserved C-terminal
region38,39, proposed to become exposed for ELMO-binding
upon receptor activation41. A recent crystal structure of
ELMO2NTD (lacking ELMO2PH) revealed that this region of
BAI1 forms an α-helical segment that interacts with
ELMO2EID42.
The molecular basis for the GEF activity of DOCK proteins was
elucidated from crystal structures of DOCK2DHR2 and
DOCK9DHR2 in complex with their cognate GTPases RAC and
CDC42, respectively31,43,44, showing that GDP release and dis-
charge of the activated GTP-bound CDC42 and RAC are catalysed
by a universal invariant valine residue that functions as a nucleotide
sensor44. However, the regulation of DOCK proteins and the signal
transduction events responsible for their activation are poorly
understood. It is not yet known how ELMO proteins regulate
DOCK-mediated GEF activity or how effector proteins such as
RHOG and BAI receptors regulate DOCK−ELMO GEF activity. To
understand the molecular architecture and mechanism of DOCK
−ELMO GEFs, we have used cryo-electron microscopy to deter-
mine structures of DOCK2−ELMO1 alone and as a ternary com-
plex with nucleotide-free RAC1, and combined this with a crystal
structure of ELMO2RBD in complex with RHOG. The binary
DOCK2−ELMO1 complex adopts a closed, auto-inhibited
conformation, whereas in the DOCK2−ELMO1−RAC1 ternary
complex, DOCK2−ELMO1 adopts an open, active conformation
through a conformational change of the ELMO1 subunit. This
exposes binding sites for RAC1 on DOCK2DHR2, with ELMO1 also
directly contacting RAC1 to promote binding to DOCK2−ELMO1.
Binding sites for RHOG and BAI GPCRs on ELMO1 also become
accessible in the active, open conformation. Our study suggests a
model for how upstream regulators control DOCK2 activation
through a conformational change of ELMO1, thereby relieving
autoinhibition.
Results
Cryo-EM structure determination of DOCK2−ELMO1−RAC1.
We prepared the human DOCK2−ELMO1 complex using the
baculovirus-insect cell expression system (Supplementary Fig. 1a).
The molecular weight of the complex of ~600 kDa estimated by
size exclusion chromatography (Supplementary Fig. 1b) indicated
the formation of a tetramer formed of two DOCK2−ELMO1
protomers. This is consistent with the observation that DOCK2
homo-dimerization is required for DOCK2-mediated RAC acti-
vation in vivo and for lymphocyte migration34, and with
previous DHR2 domain crystal structures31,43,44. Purified
DOCK2−ELMO1 forms a stable complex with nucleotide-free
RAC1 (Supplementary Fig. 1a, b), which was further stabili-
zed by crosslinking to avoid disassociation during cryo-EM
grid preparation. We then analysed the structure of the
DOCK2−ELMO1−RAC1 complex by single particle cryo-EM.
Examination of raw particle images and reference-free 2D class
averages indicated a considerable degree of structural flexibility
(Supplementary Fig. 1c–e), limiting the resolution of the overall
3D reconstruction. To improve the EM density map quality, we
generated two particle sets, each with one protomer subtracted
from the original images. Refinement of the combined
particles resulted in an EM density map with an overall resolution
of 4.1 Å (Supplementary Fig. 2a, b). The DHR2 domain was the
best-resolved feature, with other domains resolved at lower reso-
lution (Supplementary Fig. 2c). To improve the resolution of
individual structural segments, we performed focussed 3D classi-
fication on individual rigid modules, followed by focussed
refinement, and obtained reconstructed maps of the (i)
DOCK2DHR2−RAC1 catalytic module at 3.8 Å resolution,
(ii) DOCK2ARM domain at 4.2 Å, (iii) DOCK2SH3−ELMO1PH at
4.1 Å, (iv) DOCK2DHR1−DOCK2C2 at 4.6 Å and (v) ELMO1NTD
at 6.2 Å resolution (Supplementary Fig. 2b, c and Supplementary
Tables 1–3). From the whole dataset, we selected ~2% of the
particles to reconstruct a map representing the entire complex at a
resolution of 7.8 Å with twofold symmetry (Supplementary Fig. 3).
Reconstruction without imposed symmetry resulted in a very
similar map, although at lower resolution of 9.1 Å (Supplementary
Fig. 3e). Figure 1b, c shows a composite map consisting of the
individual maps of each domain together with a fitted model.
Structure of the DOCK2−ELMO1−RAC1 ternary complex.
The ternary DOCK2−ELMO1−RAC1 dimeric complex adopts an
elongated “S”-like shape with pseudo twofold symmetry, measuring
320 Å and 65 Å in the longest and shortest dimensions, respectively
(Figs. 1b, c and 2a). Both the DOCK2 and ELMO1 subunits are
assembled from a series of modular domains (Fig. 1a). In the
complex, these two subunits are arranged in a roughly parallel
manner, but because DOCK2 adopts a hook-like structure (Fig. 2b),
its N-terminal DOCK2SH3 domain is positioned to interact with the
C-terminal PxxP motif of ELMO1 (Figs. 1b and 2a). Located at the
centre of DOCK2−ELMO1−RAC1 is DOCK2DHR2, dimerized
through its A lobe, and associated with nucleotide-free RAC1
through its B and C lobes (Figs. 1b and 2a, c). Side-chains are visible
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Fig. 2 Structure of the DOCK2–ELMO1–RAC1 protomer. a Ribbon representation of the structural assembly of the DOCK2–ELMO1 protomer. DOCK2,
ELMO1 and RAC1 are highlighted in cyan, yellow-orange and red backgrounds, respectively. Insert shows the major stable interface between DOCK2 and
ELMO1 involving the six α-helical bundle. b Ribbon representation of DOCK2. Domains are labelled and colour-coded according to the domain scheme in
Fig. 1a. c Close-up view of the dimer interface formed by lobe A of the DHR2 domains of each DOCK2 monomer (shown in purple and grey-blue). Lobe A, B
and C of the DOCK2 DHR2 domains are labelled. d DOCK2ARM is rainbow-coloured from blue (N-terminus) to red (C-terminus). e Close-up view of the
interaction interface between DOCK2DHR2, ELMO1PH domain and RAC1. The switch 1 and switch 2 loops of RAC1 are coloured in yellow and green,
respectively. f Ribbon representation of ELMO1 colour-coded according to Fig. 1a.
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in this region (Supplementary Fig. 4a), allowing atomic model
building. The polybasic region C-terminal of DOCK2DHR2 (Fig. 1a)
is disordered. The region immediately N-terminal of DOCK2DHR2,
and connected to the lobe A TPR repeats of DOCK2DHR2, is a
right-handed α-solenoid domain. This is formed of 28 α-helices
composed of a mixture of ARM and HEAT repeats, termed
DOCK2ARM (Figs. 1 and 2b, d). A DALI search45 revealed the
vacuolar protein 8, an ARM repeat protein46, as the closest match
(Z score of 11.8, RMSD of 4.4 Å based on 290/568 aligned residues).
A short α-helix inserted within the ARM domain, projects out from
the main α-solenoid (Fig. 2b). This α-helical insert provides a major
site of interaction between DOCK2ARM and DOCK2SH3 (Fig. 2b).
Connected to DOCK2ARM is a globular density feature
composed of two closely packed domains. A homology model
of DOCK2DHR1 based on the crystal structure of DOCK1DHR123
was confidently fitted to the domain closest to DOCK2ARM,
consistent with the connectivity of DOCK2DHR1 and DOCK2ARM
in the protein sequence (Figs. 1a, c and 2b). The other globular
domain (residues 219–389), located between DOCK2DHR1 and
DOCK2SH3 is mainly composed of β-strands, consistent with
secondary structure predictions. A β-sandwich structure com-
posed of two β-sheets each with four anti-parallel β-strands,
predicted using Rosetta47, was fitted to this β-sheet-like cryo-EM
density (Figs. 1b, c and 2b). A DALI search45 revealed this β-
sandwich domain to be a C2-domain, with the highest structural
similarity to the C2A domain of Otoferlin48 (Z score of 4.8).
Thus, DOCK2DHR123 and DOCK2C2 share related C2-fold
architectures. DOCK2C2 is connected to the N-terminal
DOCK2SH3 and its adjacent α-helical domain by a flexible region
found to be phosphorylated in multiple mass spectrometry
studies (PhosphoSitePlus). We termed this the phosphorylation
linker (Fig. 1a, c).
The structure of the DOCK2DHR2−RAC1 module in the
context of the entire DOCK2−ELMO1−RAC1 complex (Fig. 2e)
is virtually identical to the crystal structure of the isolated
DOCK2DHR2−RAC1 complex43, with a RMSD between them of
less than 1 Å. DOCK2DHR2 forms the dimer interface of the two
DOCK2−ELMO1−RAC1 protomers (Fig. 2c), similar to other
DOCK proteins revealed by structures of their DHR2 domains
that are dimers, for example DOCK9DHR2 (Ref. 44), and as we
previously published for DOCK2DHR2 (Ref. 43). Lobe A contains
three TPR motifs with TPR3 forming the main DOCK2
dimerization interface. We produced a monomeric complex of
DOCK2−ELMO1 by mutating the dimerization interface of lobe
A of DOCK2DHR2 (Supplementary Fig. 5a–c). Cryo-EM exam-
ination showed that monomers are less stable. About 90% of
particles were disassembled, with the remaining particles
reconstructed to generate a low-resolution map (Supplementary
Fig. 5d, e). This result indicates that DOCK2 dimerization
stabilizes the complex. Although there are no clear functional
explanations for why DOCK proteins dimerize, one possibility
would be to enable cooperativity between the two catalytic sites of
the DOCK dimer.
ELMO1 comprises ELMO1NTD, ELMO1PH and C-terminal
PxxP motif (Fig. 1a). ELMO1NTD and ELMO1PH are connected
by a single α-helix termed the hinge helix (Fig. 2f). A flexible
elbow hinge at the C-terminus of the hinge helix allows mobility
of ELMO1NTD to adopt open- and closed-conformations (Fig. 3a
and Supplementary Fig. 3a, b). 3D classification showed that in
the DOCK2−ELMO1−RAC1 ternary complex, ELMO1NTD is
predominantly in the open-conformation (Supplementary
Fig. 3a–d). In this conformation, ELMO1NTD is situated above
DOCK2SH3 (Figs. 1b and 3a – left panel), whereas in the closed-
conformation, ELMO1NTD is poorly ordered, with its tip
projected towards DOCK2DHR2 (Fig. 3a – right panel). In the
ternary DOCK2−ELMO1−RAC1 complex (open-conformation),
ELMO1 adopts an elongated, gently curved shape (Fig. 2f). We
fitted the crystal structure of residues 1–520 of ELMO2
(ELMO2NTD, PDB:6IDX)42 (74% sequence identity to
ELMO1NTD) to cryo-EM density assigned to ELMO1NTD.
ELMO2NTD superimposes closely with ELMO1NTD within the
context of the DOCK2−ELMO1−RAC1 complex. ELMO1EID of
ELMO1NTD is composed of five pairs of anti-parallel α-helices
(Fig. 2f). Helix 5B is characterized by its length and protrusion
into the ELMO domain of ELMO1NTD (Fig. 2f). The EID and
ELMO domains together are common to six human proteins;
ELMO1, ELMO2, ELMO3, ELMOD1, ELMOD2, and ELMOD3.
ELMO1RBD at the N-terminus of ELMO1, adopts a ubiquitin-like
fold that is exposed to solvent and accessible for interactions with
RHOG35 and Arl437 (Figs. 1b, c and 2a).
The major and stable DOCK2−ELMO1 interface is generated
by the PH domain and C-terminal PxxP motif of ELMO1
associating with the N-terminal SH3 domain and adjacent
α-helical segment of DOCK2 (Figs. 1a, b and 2a). This is
essentially identical to the crystal structure of the isolated
DOCK2SH3−ELMO1PH assembly31. This interface comprises
two segments. First, a six-α-helical bundle produced by the
accretion of an α-helical segment adjacent to DOCK2SH3 with the
two α-helices that flank ELMO1PH31 (Fig. 2a, insert). Second, the
PxxP motif immediately C-terminal to ELMO1PH engages
DOCK2SH3, as also previously defined31 (Figs. 1b and 2a –
insert). In the cryo-EM structure of the DOCK2−ELMO1−RAC1
complex (as for the DOCK2−ELMO1 binary complex described
below), there are no direct contacts between DOCK2SH3 and
DOCK2DHR2, although such interactions may exist in DOCK2
alone as suggested by biochemical data for DOCK1 and
DOCK231,49.
In an interaction that is important for DOCK2 GEF
activity12,50–53, ELMO1PH is positioned in a groove created
between lobe B of DOCK2DHR2 and the nucleotide-free RAC1
(Figs. 1b, c, and 2a, e). This is consistent with an earlier study
showing that DOCK1 and ELMO1PH interact directly30. In
contrast to the PH domains of Dbl family GEFs such as Sos1, the
non-canonical ELMO1PH lacks critical phosphoinositide-binding
residues, and is not involved in membrane attachment30.
However, it is critical for optimal DOCK GEF activity as shown
in the nucleotide exchange assay (Supplementary Fig. 6a),
consistent with previous observations both in vitro and
in vivo12,50–53. A possible mechanism is that ELMO1 stabilizes
DOCK2 by interacting with DOCK2SH3 through ELMO1PH
(Fig. 2a). This is consistent with our observation that the purified
DOCK2 protein alone (without ELMO1) elutes from a size-
exclusion column as a broad extended peak (Supplementary
Fig. 6b), and that in negative stain EM micrographs it appears
highly heterogeneous with a tendency to aggregate (Supplemen-
tary Fig. 6c). In addition, our structure suggests that ELMO1PH
is directly involved in DOCK2 GEF activity by interacting
simultaneously with DOCK2DHR2 and nucleotide-free
RAC1, thereby stabilizing DOCK2DHR2–RAC1 interactions
(Fig. 2e).
DOCK2−ELMO1 structure shows conformational change of
ELMO1. To understand potential regulatory mechanisms that
underlie DOCK2−ELMO1 functions, we also analysed the
structure of the DOCK2−ELMO1 binary complex by cryo-EM
(Supplementary Fig. 7 and Supplementary Tables 1 and 2). 3D
classification showed that in the DOCK2−ELMO1 binary com-
plex, ELMO1NTD adopts two conformations: the open and
closed-conformations (Fig. 3b and Supplementary Fig. 7). In
~12% of DOCK2−ELMO1 particles, ELMO1NTD adopts the
open-conformation, resembling that of the DOCK2−ELMO1
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ternary complex with RAC1 (Fig. 3a, b – left panels and
Supplementary Fig. 7d). However, in the majority (~80%) of
DOCK2−ELMO1 binary complex particles, ELMO1NTD adopts a
closed-conformation (Fig. 3b – right panel). This conformation
differs slightly from the closed-conformation of the ternary
DOCK2−ELMO1−RAC1 complex. In the DOCK2−ELMO1
binary complex, ELMO1NTD is more ordered through interac-
tions with DOCK2DHR2, whereas ELMO1NTD adopts multiple
conformations in the DOCK2−ELMO1−RAC1 complex. Inter-
conversion between the open DOCK2−ELMO1−RAC1 ternary
complex and the closed DOCK2−ELMO1 binary complex
involves ELMO1NTD undergoing a rigid-body rotation of ~120°,
centred on the elbow hinge that connects ELMO1NTD and
ELMO1PH (Fig. 3c–e and Supplementary Movie 1). The closed-
conformation is stabilized by ELMO1 intra-domain contacts.
Specifically, the long flexible loop, inserted between α6 and α7 of
ELMO1ELMO, together with the neighbouring ELMO1EID, form
intimate contacts with ELMO1PH (Fig. 3e – right panel and Fig.
3f). The tip of the 16-residue α6/α7 loop of ELMO1ELMO contacts
the positively charged surface of ELMO1PH, with the invariant
Glu436 of the ELMO1ELMO α6/α7 loop inserting into a groove
created by the basic β3/β4 loop of ELMO1PH. This β3/β4 loop in
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turn projects out from ELMO1PH to insert into the acidic concave
groove formed by the ARM repeats of ELMO1EID (Fig. 3f).
In the closed-conformation of the DOCK2−ELMO1 binary
complex, ELMO1NTD also forms extensive interactions with
DOCK2 (Fig. 3b, e). Importantly, ELMO1RBD is positioned to
directly contact the RAC1-binding site of DOCK2DHR2. In
addition, ELMO1ELMO contacts DOCK2C2 (Fig. 3b, e), in
contrast with the open-conformation of ELMO1NTD which
forms no contacts with DOCK2 (Fig. 1b, c). Superimposition of
binary and ternary structures (on DOCK2DHR2) indicates that
ELMO1RBD in the closed-conformation of the DOCK2−ELMO1
binary complex, and RAC1 in the DOCK2−ELMO1−RAC1
ternary complex, overlap (Fig. 3e). Thus, in the binary state with
ELMO1NTD in the closed-conformation, ELMO1RBD sterically
occludes RAC1 engagement, suggesting an auto-inhibited con-
formation (Fig. 3e).
Another conformational difference between the binary and
ternary complexes is located in lobe C of DOCK2DHR2. In the
binary complex, lobe C is rotated away from lobes A and B of
DOCK2DHR2, with a maximum shift of ~10 Å. This allows
ELMO1RBD to engage DOCK2DHR2 (Supplementary Fig. 4b and
Supplementary Movie 1). In this conformation, as suggested by
the weaker, less well-defined EM density, DOCK2DHR2 is
more flexible than in the ternary complex. This change is mainly
due to the absence of RAC1 because lobe C adopts similar
conformations in both the open- and closed-conformations of the
DOCK2−ELMO1 binary complex (Fig. 3b).
Crystal structure of RHOG−GMP-PNP complexed with
ELMO2RBD. Binding of RHOG to ELMO may regulate RAC1
activation by spatially restricting DOCK-ELMO complexes in
cells, or through direct molecular regulation of GEF activity.
Whether ELMORBD uses a similar binding mode as RBDs found
in RAS GTPase effectors is unknown. To answer these questions,
we determined a crystal structure of activated RHOG complexed
with the RBD domain of ELMO2 (ELMO2RBD). The crystals
diffracted to 2.4 Å resolution with a single molecule in the
asymmetric unit (Fig. 4a and Supplementary Table 4). The
RHOG structure consists of six β-strands and six α-helices and is
similar in structure to other RHO family small GTPases. Char-
acteristically, RHOG nucleotide binding is coordinated by two
key regions: switch 1 and switch 2 loops which bind the terminal
γ-phosphate of GTP and a divalent magnesium ion (Fig. 4a, c).
ELMO2RBD demonstrates a classical ubiquitin-like fold consisting
of four β-strands and two α-helices, but interacts with RHOG at a
non-canonical binding interface (Fig. 4b, c).
RAS is archetypally complexed with effector RBDs through an
intermolecular, anti-parallel β-sheet consisting of β2 and β3
(switch 1) of the GTPase and β1, β2 and α1 of the RBD54. In
contrast, the interface between RHOG and ELMO2RBD comprises
both switch 1 and switch 2 regions of the GTPase (Fig. 4b, c).
Major interactions include a hydrogen bond between ELMO2
Lys9 and the main chain at RHOG Phe37, as well as a salt bridge
between Arg66 of RHOG and Glu13 of the RBD (Fig. 4c). In
addition, there are extensive hydrophobic interactions between
side chains of five RHOG residues (Val36, Phe37, Tyr64, Leu67
and Leu70) and four ELMO2 residues (Ala11, Ala19, Leu21 and
Ile74) (Fig. 4c). Each of these amino acids are highly evolutionarily
conserved in vertebrates (Supplementary Fig. 8). There is no direct
ortholog of RHOG in simple organisms, the most homologous
being RAC orthologs, but all key binding residues are conserved in
these GTPases. Interestingly, the side chain of Arg66 is surface
exposed in every available structure of a RAC GTPase. This
residue is nonetheless invariant through evolution, suggesting a
potential role in mediating protein interactions, as observed in our
structure (Fig. 4c). For ELMO, many orthologs in less complex
organisms have substitutions at Glu13, but key hydrophobic
residues and particularly Lys9 are well conserved. Thus, the crystal
structure of RHOG complexed with ELMO2 elucidates a novel
GTPase-RBD binding interface dependent on several key residues
that are highly conserved evolutionarily.
Mutations disrupt RHOG−ELMO2RBD interactions. To vali-
date the RHOG−ELMO2RBD crystal structure and identify
mutations that can disrupt formation of the RHOG−ELMO2RBD
complex, we performed binding assays using isothermal titration
calorimetry (ITC). We first determined the nucleotide depen-
dency of this interaction by performing ITC with GDP- or
GMPPNP-loaded RHOG and the ELMO2RBD. As shown in
Fig. 5a, GDP-bound RHOG does not interact with ELMO2RBD,
while GTP analogue-bound RHOG interacts with an affinity of
7.8 μM. This result is consistent with the paradigm of small
GTPase signalling, and with our structural data revealing the
interaction involves the nucleotide-sensitive switch regions.
We were unable to crystallize RHOG in the GDP bound state,
but a model based on available RHO family GDP-bound
structures demonstrates that RHOG switch 1 would move
significantly outward upon hydrolysis of GTP (Fig. 4b and
Supplementary Fig. 9a). This would likely disrupt hydrogen
bonding between ELMO2 Lys9 and the backbone of RHOG
(Fig. 4c shows the position of this residue at the binding
interface). Indeed, ITC analysis of an ELMO2 Lys9 to Ala mutant
shows the importance of this Lys side chain, as binding to RHOG
is completely abrogated (Fig. 5b). Our crystal structure revealed
this is a backbone interaction with Phe37 of RHOG switch 1
rather than a salt bridge with RHOG Asp38 (Fig. 4c). Supporting
Fig. 3 Mechanism of DOCK2–ELMO1 activation. a Comparison of the open- and closed-conformations of the DOCK2–ELMO1–RAC1 ternary complex. Left
panel: cryo-EM density map of the complex adopting the open-conformation, with model coordinates placed into the map. Right panel shows the closed-
conformation. ELMO1NTD is less well defined. b Comparison of the open- and closed-conformations of ELMO1 in the binary DOCK2–ELMO1 complex. A
ribbon representation of the model has been placed in the cryo-EM density maps. c Ribbon representation of ELMO1 shown in the open-conformation
of the ternary complex (left) and the closed-conformation of the binary complex (right). Domains are labelled and colour-coded according to Fig. 1a.
d ELMO1NTD of the ternary and binary states are superimposed. This illustrates that the conformational change between the two states is confined to a
rotation about the hinge elbow that connects ELMO1ELMO and ELMO1PH. For clarity ELMO1PH is omitted from Figure. e Two views showing superpositions
of the open DOCK2–ELMO1–RAC1 ternary complex and the closed DOCK2–ELMO1 binary complex. In both views, DOCK2 of the ternary complex is shown
as a surface representation, whereas ELMO1 is shown as a ribbon representation. This highlights the conformational rearrangement due to rotation of
ELMO1 about the elbow hinge. In the closed-conformation of ELMO1, ELMO1RBD contacts DOCK2DHR2 at the RAC1-binding site, inhibiting interactions of
RAC1 with DOCK2DHR2 (insert: ternary DOCK2–ELMO1–RAC1 complex). In the left view, the DOCK2 phosphorylation linker is labelled. In the closed-
conformation of DOCK2–ELMO1, this region is in close proximity to ELMO1ELMO and the adjacent hinge helix, suggesting that phosphorylation at this site
would favour the open active conformation. ELMO1PH of the binary and ternary complexes are coloured orange and light orange, respectively. f Details of
the interface between ELMO1PH (displayed as an electrostatic potential surface) with ELMO1NTD, specifically the ELMO1ELMO and ELMO1EID domains of
the DOCK2–ELMO1 binary complex.
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this, a RHOG Asp38 to Ala mutant binds ELMO2RBD with an
affinity of 9.0 μM, comparable to wild-type (Fig. 5c, left). A key
RHOG side chain at the binding interface is Arg66 in the switch 2
region (Fig. 4c), and ITC analysis revealed a RHOG R66A mutant
is unable to bind ELMO2RBD (Fig. 5c, right). Size exclusion
chromatography and NMR verified that the two mutants that
disrupt the RHOG-ELMORBD interaction, RHOGD38A and
ELMOK9A, were correctly folded and comparable to wild type
a
b
d
c
Fig. 4 Crystal structure of the RHOG–ELMO2RBD complex. a Structure of RHOG complexed with ELMO2RBD. The switch 1 (pink) and switch 2 (red) regions
of RHOG are highlighted. GMPPNP is shown in stick form and the bound Mg2+ ion (yellow). b Superimposition of the RHOG–ELMO2RBD structure with that of
the modelled GDP-bound RHOG (grey, based on RHOA; PDBid 1FTN). The switch 1, switch 2 and binding interface with ELMO2RBD are highlighted in the circle.
The switch 1 region of inactive RHOA is noticeably shifted outward. c Detailed view of the RHOG–ELMO2RBD binding interface. Residues involved in the
interaction are labelled and shown with side chains in stick form. d In the closed-inactive conformation of DOCK2–ELMO1, Tyr18 contacts DOCK2DHR2.
Phosphorylation of Tyr18 by TAM kinases would destabilize DOCK2DHR2–ELMO1RBD interactions, thereby stimulating DOCK2 GEF activity.
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Fig. 5 Mutations of the RHOG–ELMO2RBD interface disrupts interactions. ITC binding assay for (a) Wild-type RHOG in the inactive GDP-bound state
(left) or active GTP-bound state (right) with wild-type ELMO2RBD; (b) K9A mutant of ELMO2RBD with wild-type RHOG; and (c) D38A and R66A mutants
of activated RHOG with wild-type ELMO2RBD. For ITC assays showing no binding, the Kd was not determined (ND). The positions of these residues are
shown in Fig. 4c. The experiments were performed independently three times with similar results.
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(Supplementary Fig. 10). These data reveal that Arg66 of RHOG
and Lys9 of ELMO2 are key residues driving formation of this
complex, and corroborate the unique switch 1–2 recognition site
of the ELMO ubiquitin-fold RBD (Supplementary Fig. 9b). While
direct contact with the RAS switch 2 region is not typical of RAS-
RBD interactions (Supplementary Fig. 9c–e), there are two RBD
domains from RAS effectors that do contact switch 2 (via
hydrophobic residues at the bottom of an auxiliary α-helix):
RASSF5/NORE1A55 and AF6/AFDN56 (Supplementary Fig. 9f,
g). Their binding mode, however, is entirely distinct from
RHOG−ELMO2RBD which we suggest is a new class of GTPase-
RBD complex.
The closed conformation of DOCK2−ELMO1 is auto-inhibited.
The interaction of ELMO1NTD with DOCK2DHR2 in the closed
DOCK2−ELMO1 binary complex, such that ELMO1RBD occludes
the RAC1-binding site of DOCK2DHR2 suggested the possibility
that ELMO1NTD suppresses DOCK2 activity. We therefore tested
the effects of removing the steric hindrance caused by ELMO1NTD
to RAC1 binding and GEF activity. When ELMO1NTD was
deleted (DOCK2−ELMO1ΔNTD), the GEF activity increased by
60% (Fig. 6a, b and Table 1). This is consistent with the idea that
the closed-conformation of ELMO1NTD represents an auto-
inhibited state of DOCK2−ELMO1.
Superimposing the crystal structure of the ELMO2RBD−RHOG
complex onto ELMO1RBD of the DOCK2−ELMO1 complexes
showed that for DOCK2−ELMO1−RAC1, with ELMO1NTD in
the open-conformation, the RHOG-binding site on ELMO1RBD is
readily accessible for RHOG engagement (Fig. 6c). However, the
binding of RHOG to ELMO1RBD of the DOCK2−ELMO1 binary
complex, with ELMO1NTD in the closed-conformation, is
sterically occluded by DOCK2DHR2 (Fig. 6d). Thus, RHOG
binding to DOCK2−ELMO1 is incompatible with the closed-
conformation. This suggests that RHOG engagement by
ELMO1RBD might destabilize the closed conformation and
promote the open-conformation, thereby relieving auto-
inhibition. In accord with this suggestion, RHOG activates
RAC1 by direct interaction with ELMO1RBD in vivo in the
context of the plasma membrane35.
We also compared the crystal structure of the ELMO2−BAI1
complex42 with our DOCK2−ELMO1 complex (Fig. 6c, d). This
revealed that in the closed-conformation of DOCK2−ELMO1,
the binding site on ELMO1EID for the C-terminal helix of the
GPCR BAI1 is sterically occluded by ELMO1PH (Fig. 6d),
precluding BAI1 engagement to the auto-inhibited state of
DOCK2−ELMO1. By contrast, in the open-conformation, the
BAI1-binding site is accessible (Fig. 6c). Thus, similar to RHOG
binding to ELMO1RBD, engagement of BAI1 to ELMO1EID would
promote the open, active conformation of DOCK2−ELMO1,
stimulating its GEF activity. The mode of binding of BAI1 is
conserved with BAI2 and BAI3 which interact with ELMO
through a similar C-terminal helix39.
The Tyro3, Axl, and Mer receptor tyrosine kinases (TAM
kinases) phosphorylate Tyr18 and Tyr48 of ELMO1RBD to
promote RAC activation and cell migration57. In the closed-
conformation of the binary DOCK2−ELMO1 complex, Tyr18 is
located at the ELMO1RBD−DOCK2DHR2 interface, whereas
Tyr48 is solvent exposed (Fig. 4d). This suggests that phosphor-
ylation of Tyr18 would destabilize the auto-inhibited conforma-
tion of DOCK2−ELMO1 in favour of the active state, consistent
with the ability of TAM kinases to activate RAC.
Phosphorylation of DOCK2 promotes RAC1 signalling. Phos-
phorylation of DOCK1 on Tyr1811 is a possible mechanism for
activation since it correlates with its activity toward RAC158,59.
While a similar site is not conserved within the equivalent C-
terminal disordered region of DOCK2, the N-terminus of
DOCK2 is instead phosphorylated on three proximal residues
Tyr209, Tyr212 and Ser213 identified in multiple mass spectro-
metry studies (PhosphoSitePlus) (Fig. 7a). Our structure reveals
that these sites are located within a phosphorylation linker seg-
ment (residues 208–218) connecting the helical region immedi-
ately C-terminal to DOCK2SH3 with DOCK2C2 (Fig. 1a, c). In the
closed DOCK2−ELMO1 binary complex, this region, disordered
in our structure, forms an interface with the ELMO1ELMO
domain when the complex is auto-inhibited (Fig. 3e, left panel).
As shown in Fig. 7a, alignment of different mammalian
DOCK2 sequences surrounding these phosphorylation sites
reveals that Tyr209, Tyr212 and Ser213 are conserved with the
exception of X. tropicalis. These observations led us to reason that
phosphorylation of DOCK2 at these sites may be a mechanism
for the relief of the auto-inhibited state of the DOCK2−ELMO1
complex. To test this hypothesis, we generated a phospho-
mimetic DOCK2 mutant where Tyr209, Tyr212 and Ser213 were
mutated to Glu (DOCK2YYS/EEE). We tested whether expressing a
phospho-mimetic DOCK2 in cells would affect its GEF activity.
By performing a GST-PAK pulldown assay to assess the levels of
RAC activation, co-overexpressing DOCK2YYS/EEE with ELMO1
led to higher active RAC1 levels, compared with DOCK2WT
(Fig. 7b), suggesting that DOCK2 phosphorylation on these sites
can lead to increasing DOCK2 RAC1 GEF activity in
HEK293T cells. We then reasoned that if DOCK2YYS/EEE can
promote RAC1 GTP-loading, then it should enhance cell
migration and invasion. Using Boyden migration and Matrigel-
invasion assays, we found that co-expression of DOCK2YYS/EEE
with ELMO1 and CRKII in HeLa cells led to higher cell migration
and invasion compared with DOCK2WT (Fig. 7c, d). This was
further confirmed in wound healing as well as time-lapse live
imaging assays of cells co-expressing ELMO1 and CRKII with
either DOCK2YYS/EEE or DOCK2WT (Fig. 7e, f, Supplementary
Movie 2). CRKII was included because in functional assays, the
RAC1-dependent activities of DOCK1 and DOCK2 are maximal
when co-expressed with both ELMO1 and CRKII12,30. Collec-
tively, these data reveal a mechanism whereby phosphorylation
of DOCK2 in the phosphorylation linker likely alleviates
DOCK2−ELMO1 auto-inhibition to catalyse RAC1 activation to
enhance cell migration and invasion.
ELMO1NTD is essential for RAC1 signalling by DOCK2 in
cells. In the auto-inhibited DOCK2−ELMO1 structure, the
region of ELMO1NTD, in particular ELMO1RBD, occludes the
DOCK2DHR2 RAC1-binding site. Removal of ELMO1NTD
increased the activity of the DOCK2−ELMO1 complex in vitro
(Fig. 4a, b). We aimed to determine if removing ELMO1NTD
would facilitate DOCK2-dependent RAC1 binding or activation
in cells. We truncated the first 529 residues from ELMO1 to
generate a mutant that lacks the N-terminal domain
(ELMO1ΔNTD) (Fig. 8a). We tested whether the expression of
ELMO1ΔNTD in comparison to ELMO1WT has an effect on
DOCK2 GEF activity by performing a GST-PAK pulldown assay
to assess the levels of active RAC1. Co-expression of DOCK2 with
ELMO1WT led to a significant increase in active RAC1 levels
whereas co-expressing DOCK2 with ELMO1ΔNTD led to a small
but significant decrease in the levels of active RAC1 in compar-
ison to the conditions with ELMO1WT (Fig. 8b). These results are
consistent with a view suggesting that ELMO1NTD is required to
target the DOCK2−ELMO1 complex to the membrane for effi-
cient DOCK2-mediated RAC1 activation. To directly test if
DOCK2DHR2 is more accessible to bind RAC1 in the conditions
where ELMO1ΔNTD is co-expressed, we conducted nucleotide-
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free RAC1G15A pulldowns. GEFs form a stable complex with their
target GTPases when in a nucleotide-free state60. Such an inter-
action is supported by structural evidence for DOCK2DHR2-
RAC144. Hence, we generated the nucleotide-free RAC1G15A
mutant, the equivalent of RHOAG17A. We found that RAC1G15A
binding to DOCK2 was minimally but significantly decreased
upon expression of ELMO1ΔNTD compared with conditions with
ELMO1WT (Fig. 8c). Hence, this suggests that the decreased
RAC1 activation upon expression of ELMO1ΔNTD might be due
to decreased levels of the DOCK2−RAC1 complex. Functionally,
a b
c d
Fig. 6 ELMO1NTD auto-inhibits DOCK2–ELMO1. a, b GEF activity data. ELMO1 stimulates DOCK2 GEF activity. Deleting ELMO1NTD stimulates
DOCK2–ELMO1 GEF activity 60%. Disrupting the DOCK2 dimerization reduces GEF activity by ~60%. a Experimental data for RAC1 at 0.8 μM. There was no
observable spontaneous GDP exchange without the GEF. GEF activity data was monitored by the exchange of fluorescent mant-GTP following an injection of
GDP after 1 min (indicated by arrow). b Rates as a function of RAC1 concentration. The initial rates of exchange at increasing substrate (mant-RAC)
concentrations were fitted to a Michaelis-Menten equation with the resultant constants shown in Table 1. Data are presented as mean values with error bars of
+/− one standard deviation. The experiment shown in (a) and (b) was performed six times. c The crystal structure of the RHOG–ELMO2RBD complex was
superimposed onto the modelled ELMO1RBD of DOCK2–ELMO1–RAC1 (shown in surface representation with ELMO1NTD in the open-conformation). d The
crystal structure of the RHOG–ELMO2RBD complex was superimposed onto ELMO1RBD of DOCK2–ELMO1 (shown in surface representation with ELMO1NTD in
closed-conformation). This shows that RHOG-binding site on ELMO1RBD is exposed in DOCK2–ELMO1–RAC1, whereas in the binary DOCK2–ELMO complex,
with ELMO1 in the down conformation, the RHOG-binding site on ELMO1RBD is occluded by DOCK2DHR2. Modelling the ELMO2NTD–BAI1 complex onto
ELMO1NTD of the DOCK2−ELMO1 binary complex (closed-conformation) shows that BAI1 bound to the ELMO1EID domain would clash with ELMO1PH (d), but
not in the ternary DOCK2–ELMO1–RAC1 complex (c). Thus, RhoG and BAI1 would only bind to the activated conformation of the binary DOCK2−ELMO1
complex with the ELMO1NTD in the open-conformation with the DOCK2DHR2−RAC1 binding site exposed. Source data are provided as a Source Data file.
Table 1 Initial rate constants of nucleotide exchange reactions of DOCK2-ELMO1 complexes.
DOCK2-ELMO1 DOCK2-ELMO1ΔNTD Monomer: DOCK2-ELMO1 DOCK2DHR2
Km (µM) 0.17 0.28 0.04 0.13
Vmax (arbitrary units. s−1) 1025 1604 438 720
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co-expression of DOCK2 with ELMO1ΔNTD and CRKII led to a
decrease in the migration and invasion of HeLa cells, using
Boyden migration and Matrigel-invasion assays, respectively
(Fig. 8d, e). These results were further confirmed in wound
healing and time-lapse live imaging assays, where cells expressing
ELMO1ΔNTD were less motile when compared with cells
expressing ELMO1WT (Fig. 8f, g and Supplementary Movie 2).
Collectively, these data further confirm the importance of
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ELMO1NTD for optimal RAC1 activation and for the induction of
RAC1-mediated cell migration and invasion in cells.
Discussion
Our structure of DOCK2−ELMO1 reveals how the modular
organization of two multiple domain subunits associate to form the
binary complex. Conformational changes within ELMO1 relieves
auto-inhibition suggesting a model for how interdependent ligand
binding to multiple sites on both DOCK2 and ELMO1, and
DOCK2−ELMO1 phosphorylation, regulates DOCK2 GEF activ-
ity (Fig. 9a). Contacts between domains within subunits create
fairly rigid structures, with the only major conformational
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Fig. 8 ELMO1NTD is required for RAC1 signalling mediated by DOCK2. a Schematic of full length ELMO1 and ELMO1ΔNTD domains. b Expression of
ELMO1ΔNTD leads to less RAC1 activation when compared with ELMO1WT expression. 293 T cells transfected with the indicated plasmids were subjected
to a RAC activation assay (GST-PAK1 PBD pulldown). RAC activation levels were detected by western blotting and quantified using ImageJ. c DOCK2WT
binds less nucleotide-free RAC1 upon expression of ELMO1ΔNTD. Lysates of 293 T cells expressing the indicated plasmids were used for GST-Rac1G15A
pulldown. Levels of Flag-DOCK2 bound to RAC1 were detected by western blotting and quantified by ImageJ. The experiments in (b) and (c) were
performed four times. d, e Boyden migration (d) and invasion (e) assay performed with HeLa cells transfected with the indicated plasmids. Number of cells
migrated were counted via DAPI staining of the membrane. (n= 3, 10 fields used at 10X per condition per experiment). f Quantifications of transfected
HeLa cells displacement in a wound healing assay. Experiments were performed four times, imaging four fields using a 10X objective per condition.
g Average speed of transfected HeLa cells time-lapse imaged for 6 h. Average speed was quantified using manual tracking on ImageJ. Experiments
were performed four times, imaging four fields using a 10X objective per condition. Data were analysed from three experiments and expressed as mean ± s.
e.m. Two-tailed unpaired student’s t-test was used (d, e, f, g) and Mann–Whitney test (b, c). (*p= 0.0286 (b, c); **p= 0.0014 (d); ***p= 0.000089 (e);
*p= 0.0216 (f); **p= 0.0058 (g)). Source data are provided as a Source Data file.
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variability resulting from rotation about the hinge elbow con-
necting ELMO1NTD and ELMO1PH. Interactions between the two
subunits are centred on stable and invariant contacts between the
N-terminal SH3 and helical domains of DOCK2 and the PH
domain and poly-Pro segment at the C-terminus of ELMO1. The
binary DOCK2−ELMO1 complex adopts two conformational
states. In the closed, auto-inhibited conformation, ELMO1NTD is
positioned to form extensive contacts with ELMO1PH, DOCK2C2
and DOCK2DHR2 (Fig. 3e – right panel). Importantly, the latter
interaction involving ELMO1RBD blocks access of DOCK2DHR2 for
RAC1, thereby suppressing DOCK2−ELMO1 GEF activity. In the
alternative open, active conformation, ELMO1NTD has swung
about the elbow hinge, exposing multiple binding sites on both
DOCK2 and ELMO1 (Fig. 9). ELMO1 adopts the same open-
conformation in the DOCK2−ELMO1−RAC1 ternary complex,
indicating that the open-conformation of DOCK2−ELMO1
represents the active state of the complex. The bindings sites on
DOCK2 and ELMO1 that become exposed in the open con-
formation comprise the RAC1-binding site on DOCK2DHR2, the
BAI-binding site on ELMOEID, and the RHOG and Arl4A binding
site on ELMORBD. Exposure of the ELMOEID-binding site on BAI
GPCRs upon receptor activation could then allow binding of
ELMO and recruitment of DOCK−ELMO complexes to the
plasma membrane41. Accessibility of the PIP3-binding site on the
DHR1 domain23 of DOCK2 is unaffected by the conformational
change of ELMO1NTD (Fig. 3e). Notably, the membrane attach-
ment sites of the DOCK2−ELMO1 complex through PIP3
engagement of DOCK2DHR1, and RAC1, mediated by its
C-terminal prenylation, are situated on the same face of the
DOCK2−ELMO1−RAC1 ternary complex (Fig. 9b).
Activation of DOCK2 by relief of the ELMO1RBD-mediated
auto-inhibition requires a conformation change in the
a
b
Fig. 9 Schematic of conformational changes of DOCK2–ELMO1 and membrane attachment model. a In the DOCK2–ELMO1–RAC1 ternary complex,
ELMO1NTD adopts the open conformation with binding sites for RAC1, RHOG and BAI1 exposed on DOCK2DHR2, ELMO1RBD and ELMO1EID (on
ELMO1NTD), respectively. In the closed, auto-inhibited state of the DOCK2–ELMO1 binary complex (the dominate state for DOCK2–ELMO1), rotation of
ELMO1NTD by 120° about an elbow hinge connecting ELMO1NTD with ELMO1PH causes ELMO1NTD to form contacts with DOCK2DHR2 and ELMO1PH.
These new interfaces create an auto-inhibited state that occludes binding sites for RAC1, RHOG and BAI. Phosphorylation of ELMO1 on either the
phosphorylation linker (Fig. 1c) or Tyr 18 of ELMO1RBD (Fig. 4d) would disrupt the closed state. The view is similar to Figs. 3a, b and 6d. b Membrane
attachment sites for DOCK2 and RAC1 are situated on the same face of the DOCK2−ELMO1−RAC1 complex. PIP3 binds to a site defined by the L1 loop of
DOCK2DHR1 incorporating Lys437, Lys440 and Lys444, whereas RAC1 attaches to the membrane through a prenyl group attached to Cys189. Leu177
denotes the last ordered residue of the RAC1 crystal structure.
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ELMO1NTD. We propose that this could be regulated by two
mechanisms. First, the binding of upstream regulators to distinct
domains of ELMO, whose binding sites are blocked in the auto-
inhibited state, for example RHOG or Arl4A to ELMORBD and
BAI receptors to ELMOEID, would promote the active con-
formation. Second, phosphorylation of DOCK2 within its phos-
phorylation linker region, and ELMO1RBD, whose sites are
buried in the auto-inhibited state, would also promote the
active conformation. Conceivably, prior phosphorylation of
DOCK2−ELMO1 relieves auto-inhibition to expose binding sites
for both BAI receptors and RHOG, recruiting DOCK2−ELMO1
to the cell membrane where RAC is localized. Because
ELMO interacts with numerous additional proteins, such as
the membrane protein ClipR-59, required for myoblast fusion61,
the model we propose here for relief of ELMO-mediated
auto-inhibition may be general for numerous regulators of the
DOCK−ELMO−RAC signalling module.
Methods
Cloning and mutagenesis. The coding sequence for human DOCK2 and ELMO1
were amplified by PCR using primers 35–46 (see Supplementary Table 5 for a list
of primers used in this study) and cloned into pF1 and pU1 plasmids, respec-
tively62. A double StrepII tag together with a TEV cleavage site were attached to the
C-terminus of DOCK2 and ELMO1. For RAC1 protein purification, pGEX-RAC1
was a gift from Jonathan Chernoff (Addgene plasmid # 12200). To disrupt DOCK2
dimerization, DOCK2(Y1315A/L1322A/Y1329A)-pF1 was prepared using USER meth-
odology63 using primers 31–34. ELMO1ΔRBD and ELMOΔNTD were modified
based on ELMO-pU1 by deletion of residues 2–79 and 2–529 with primers 27–30.
Human RHOG (GeneID 391; amino acids 1–179) was cloned into the pDEST17
bacterial expression vector using Gateway technology, with a thrombin cleavage
site inserted between the poly-HIS tag and the RHOG coding sequence using
primers 15 and 16 (Supplementary Table 5). A sequence encoding the N-terminal
RBD domain of murine ELMO2 (GeneID 140579; amino acids 1–80) was cloned
into a bacterial expression vector (pBR322) with an N-terminal glutathione S-
transferase (GST) tag. To confirm the interaction interface of the RHOG and
ELMO2 complex, RHOGD38A, RHOGR66A and ELMO2K9A were prepared by
the site directed mutagenesis method using primers 17–22. The plasmid pU1-
hELMO1 was used to generate pCS-6Myc-hELMO1 and pCS-6Myc-hELMO1ΔNTD
by the Gateway cloning system using primers 1–4 (Supplementary Table 5).
pCXN2-FLAG-hDOCK2 was a kind gift from Dr. Michiyuki Matsuda (Kyoto
University) and was used to generate the pCXN2-FLAG-hDOCK2YYS/EEE mutant
using the HiFi Gibson Assembly technology using primers 5–14 (Supplementary
Table 5). pEGFP-C2-CRKII was a kind gift of Dr. Kristiina Vuori (Sandford
Burnham Prebys Medical Discovery Institute).
Expression and purification. To express and purify the DOCK2–ELMO1 com-
plexes, DOCK2−ELMO1, monomeric DOCK2−ELMO1, DOCK2−ELMO1ΔNTD
and DOCK2−ELMO1ΔRBD complexes were co-expressed in High Five™ cells (BTI-
TN-5B1–4) (ThermoFisher) for 2 days. The DOCK2−ELMO1 pellet was lysed in a
buffer of 50 mM Tris HCl (pH 8.0), 200 mM NaCl, 2 mM DTT, 2 mM benzami-
dine, 1 mM EDTA, 0.2 mM PMSF and then loaded onto a Strep-Tactin® Column
(QIAGEN) and the Strep-tagged complex was eluted with 5 mM desthiobiotin. The
Strep-tag was cleaved by TEV protease overnight at 4 °C. The complex was further
purified using Resource Q anion exchange chromatography and Superose 6 size
exclusion chromatography. DOCK2DHR2 and GST-RAC1 were expressed in E. coli
B834 (DE3) cells (EMD Millipore) transformed with the pRare2 plasmid
(Addgene) grown overnight at 20 °C. GST-RAC1 was purified using glutathione
superflow (GE-Healthcare) followed by removal of the GST-tag using thrombin
protease (Sigma). Cleaved RAC1 was further purified by Superose 6 size exclusion
chromatography. The 5 mM EDTA was added to the buffer (50 mM Tris HCl (pH
8.0), 200 mM NaCl and 2 mM DTT) to remove nucleotide. DOCK2DHR2 cell
pellets were resuspended in five volumes of ice-cold lysis buffer (50 mM Tris HCl
(pH 8.0), 350 mM NaCl, 2 mM imidazole, 2 mM β-mercaptoethanol, 10% (v/v)
glycerol). His6-Rac1 was purified by subjecting the lysate to Talon resin (Sigma
Aldrich) and then to an S300 size exclusion column (GE Healthcare). To
remove nucleotide, 5 mM EDTA was added to the buffer in the size exclusion
purification step43. To prepare the DOCK2−ELMO1−RAC1 ternary complex, the
DOCK2−ELMO1 binary complex and RAC1 were incubated in 1:2 molar ratio on
ice in a buffer of 20 mM Hepes (pH 8.0), 200 mM NaCl for 30 min and crosslinked
by 0.03% glutaraldehyde for 10 min on ice. The reaction was quenched by 50 mM
Tris HCl (pH 8.0) and loaded onto a Superose 6 column for further purification.
Size exclusion chromatography for the DOCK2–ELMO1 complex wild type and
dimer mutant (Y1315A/L1322A/Y1329A: DOCK2YLY/AAA) was performed on a
SuperdexTM 200 5/150GL column, in gel filtration buffer 50 mM Tris HCl (pH 8.0),
200 mM NaCl and 2 mM DTT.
For RHOG purification, recombinant plasmids were transfected into
Escherichia coli BL21 (DE3) CodonPlus cells (Agilent Technologies) and grown at
37 °C in Luria-Bertani medium with 100 μg/ml ampicillin up to optical density (at
600 nm) of 0.6. Protein expression was induced by the addition of 0.5 mM
isopropyl-D-thiogalactopyranoside (IPTG) at 20 °C and cultures were grown for
18 h. Cells were lysed using sonication in 20 mM Tris HCl (pH 7.5), 150 mM NaCl,
5 mM MgCl2, 10% (v/v) glycerol, 0.4% Nonidet P-40, protease inhibitors, and
either 1 mM DTT or 5 mM β-mercaptoethanol. Lysates were cleared by
centrifugation and incubated with nickel-nitrilotriacetic acid or GSH resin for
1–2 h at 4 °C. After washing in high-salt buffer (20 mM Tris HCl (pH 7.5), 500 mM
NaCl, 5 mM MgCl2, and 1 mM DTT or 5 mM β-mercaptoethanol), His-tagged
proteins were eluted with 250 mM imidazole followed by thrombin cleavage. GST
fusions were cleaved with thrombin directly on GSH resin overnight at 4 °C. For
nucleotide exchange, RHOG proteins were incubated at 37 °C in the presence of
10 mM EDTA and a tenfold molar excess (nucleotide:protein) of GMPPNP
(Sigma-Aldrich) for 10 min. 20 mM MgCl2 was added and the sample was placed
on ice. Cleaved and nucleotide-loaded proteins were purified on a HiLoad 26/600
Superdex 75 prep-grade column with a buffer consisting of 20 mM Tris HCl (pH
7.5), 100 mM NaCl, 5 mM MgCl2, and 1 mM dithiothreitol. Fractions containing
purified protein were pooled, concentrated to 10 mg/mL and stored at −80 °C prior
to crystallization.
Single colonies of BL21 (DE3) CodonPlus bacteria (Agilent Technologies)
transformed with GST-RAC1G15A or GST-PAK-PBD were grown in LB with
antibiotics overnight at 37%. Then 24 h later, the bacteria cultures were grown in
5x the volume of LB with antibiotics and 0.1 M IPTG. These cultures were then
shaken at 37 °C for 3 h. Bacterial pellets were obtained by centrifugation and
suspended in 4 mL of lysis buffer (1xPBS, 1%Triton, 1x complete protein
protease inhibitor (Roche)). After rupturing the cell membranes by sonication 3x
of 30 s, lysates were cleared by centrifugation and supernatants containing the
GST-proteins of interests were incubated with GST-beads for 1 h for affinity
purification. The GST-beads were then washed and resuspended in 0.1% Triton-
PBS.
Fluorescence kinetics analysis. The RAC1-mant GTP complex was prepared by
incubating 2 μM RAC1 with 10 μM 2’/3’-O-(N’-methylanthraniloyl)guanosine 5′-
O-triphosphate GTP (mant GTP) for 15 min at 20 °C in reaction buffer (50 mM
Tris HCl (pH 8.0), 200 mM NaCl, 10 mM MgCl2, 2 mM DTT)44. Fluorescence
experiments were performed using a PHERAstar FS Plate reader (BMG LabTech).
In the absence and presence of 0.2 μM GEF, varying concentrations of RAC1-mant
GTP (from 0.2 to 1.6 µM) were incubated in reaction buffer (50 mM Tris HCl (pH
8.0), 200 mM NaCl, 10 mM MgCl2, 2 mM DTT) for 10 min at 22 °C. The release
reaction was initiated by injection of 100 μM GDP. The fluorescence signals
(excitation wavelength 350 nm and emission wavelength 450 nm) were monitored
every 0.6 s. The initial rates of exchange were fitted and the average from triplicate
assays were plotted against concentration of substrate (RAC1-mant-GDP) and
fitted to a Michaelis-Menten equation. Data were analysed using PRISM 8.2.1
(GraphPad Software). Graphs were plotted after subtraction of the uncatalysed
nucleotide release rate.
Electron microscopy. Freshly purified DOCK2 samples (DOCK2−ELMO1−RAC1,
DOCK2−ELMO1 or monomeric DOCK2−ELMO1−RAC1 mutant) were first
visualized by negative-staining EM to check the sample quality. For cryo-EM grids
preparation, DOCK2 samples were treated by 0.025% glutaraldehyde for 10min
on ice before a size exclusion chromatography purification using a Superose 6
Increase column (GE Healthcare) to remove aggregates. Without cross-linking
treatment, most particles were found disassembled on cryo-EM grids. Aliquots of 3 µl
samples at ~0.2mg/ml were applied onto glow-discharged Quantifoil R1.2/1.3
holey carbon grids. The grids were incubated for 30 s at 4 °C and 100% humidity and
then blotted for 8 s and plunged into liquid ethane using a Vitrobot III (Thermo
Fisher).
DOCK2−ELMO1−RAC1 was imaged by a Thermo Fisher Scientific Titan
Krios electron microscope at the MRC Laboratory of Molecular Biology (MRC-
LMB) that was operated at an acceleration voltage of 300 kV and at a nominal
magnification of 81,000 (resulting a calibrated physical pixel size of 1.43 Å/pixel),
and a Gatan K2 summit detector that was installed after a GIF Quantum energy
filter and operated with a slit width of 20 eV. In total, 1,338 micrographs were
collected manually using K2 super-resolution mode. Each micrograph was exposed
for 16 s at a dose rate of 5 electrons/pixel/sec and saved as 20 movie frames.
Calculated defocus values are in a range of −1.5 to −3.2 µm. A second batch of 576
micrographs was collected on the same microscope at a nominal magnification of
64,000 (resulting calibrated pixel size of 1.76 Å/pixel).
DOCK2− ELMO1 was imaged by two Titan Krios microscopes, one at the
MRC-LMB and the other at eBIC, Diamond Light Source, operated at similar
conditions to those for imaging DOCK2−ELMO1−RAC1 unless specified below.
From MRC-LMB, 566 micrographs were collected manually using a K2 detector
in counting mode at a nominal magnification of 64,000 (resulting calibrated
pixel size of 1.76 Å/pixel). From eBIC, 4,025 micrographs were collected
automatically by EPU using a K2 detector in counting mode (with calibrated pixel
size of 1.34 Å/pixel).
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EM image processing. All movie frames were aligned using MotionCor264 before
subsequent processing. The contrast transfer function parameters were calculated
using Gctf65.
For DOCK2−ELMO1−RAC1, particles in 282 pixels x 282 pixels were selected
by the automatic particle picking module in RELION 1.4, using reference-free 2D
class averages from manually selected particles as templates66–69. The following
steps were performed to exclude bad particles from the dataset. (1) Automatically
picked particles in each micrograph were screened manually to remove ice
contaminations; (2) Remaining particles were extracted and sorted by similarity to
template images used for automatic picking, and those particles with low Z-scores
were deleted; (3) 2-dimensional classification was performed and particles in
bad classes with poorly recognizable features were excluded. 245,763 good particles
were selected from two distinct datasets (Fig. 2a). For the second dataset collected
at a lower magnification (1.76 Å/pixel), particles were rescaled to 1.43 Å/pixel when
performing particle extraction in RELION66–69. Specifically, a box size of 230 pixels
and a re-scaled box size of 282 pixels were used to scale the particles in Fourier
space (230 pixels * 1.76 Å/pixel/282 pixels= 1.4354 Å/pixel).
To generate an initial model for 3D refinement, e2initialmodel.py program in
EMAN2 package45 was used with 10 selected 2D average images from RELION 2D
classification. Initial refinement with a subset of 80,411 particles resulted in a map
with 12~15 Å resolution. When a mask with ordered regions comprising the
DOCK2DHR2−RAC1 dimer, DOCK2ARM, DOCK2DHR1, DOCK2C2 and
DOCK2SH3−ELMO1PH was used (Supplementary Fig. 1e), focussed refinement
resulted in a significantly improved map at 6.6 Å resolution. By making a mask
based on the improved map that only included strong densities, the refinement
resulted in a 6.1 Å resolution map. Refinement using all particles resulted in a map
at an overall resolution of 4.6 Å. The results indicated that flexibility was seriously
influencing the alignment and two monomers needed to be separated to improve
the resolution. We then prepared monomeric DOCK2−ELMO1−RAC1 complex
by mutating the dimerization interface of DOCK2DHR2 (Y1315A/L1322A/
Y1329A). Although we could purify monomeric complex, the complex was very
unstable on cryo-EM grids and we were not able to improve the resolution by this
approach (Supplementary Fig. 6).
To improve the resolution, we separated two monomers computationally
using signal subtraction70. With a mask that includes one monomer of
DOCK2−ELMO1−RAC1 and the DOCK2DHR2−RAC1 region from the other
monomer, we performed a refinement to align all particles. We then subtracted
the aligned monomer (all of the monomer but not DOCK2DHR2−RAC1 region)
from original particles to create a subtracted dataset A. With dataset A, we then
performed a refinement with the mask of the other monomer map. We then
used the alignment parameters to subtract the other monomer from the original
dataset to create subtracted dataset B. By combining datasets A and B, a map
was reconstructed to 4.1 Å resolution (Supplementary Fig. 2a, b).
From local resolution map and further 3D classification, we observed
flexibility of individual parts/domains. For instance, DOCK2ARM and the
DOCK2SH3−ELMO1PH assembly can be distinguished into two conformations by
3D classification, respectively. To further improve the resolution of each part, we
performed focussed refinement or focussed 3D classification in combination with
refinement. A summary of all EM reconstructions obtained is listed in
Supplementary Tables 1 and 2.
For DOCK2−ELMO1, data processing followed a similar procedure. The
resolutions were generally lower compared with DOCK2−ELMO1−RAC1, likely
due to the DOCK2−ELMO1 sample being less stable. However, the ELMO1NTD
region was improved and showed more detailed structure.
Map visualization. Figures were generated using Pymol and Chimera71.
DOCK2−ELMO1 model building. Initial model building for each domain was
based on maps from DOCK2−ELMO1−RAC1, except for ELMO1NTD that was
based on a map from DOCK2−ELMO1. For DOCK2DHR2−RAC1, the crystal
structure (PDB: 2YIN)43 was fitted to the density map using “fit to map” program
in Chimera71 and then rebuilt in COOT72 guided by side-chain densities (Sup-
plementary Fig. 4a). For the ARM domain, 3D structure predictions from
PHYRE273 and I-TASSER74 were used to as guide for determining connections of
helices, but the final map was built with poly-alanine. For the DHR1 domain, a
structure model was firstly built using PHYRE2 based on the crystal structure of
DOCK1DHR123 and then fitted to the cryo-EM density map. For DOCK2C2, a
structure model was built ab initio using ROSETTA47 and fitted into the
density map. For the DOCK2SH3−ELMO1PH assembly, the crystal structure of this
region (PDB: 3A98)31 was fitted as a rigid-body. The N-terminal extension of
DOCK2 (a loop and α-helix) and ELMO1 (α-helix) beyond the crystal structure
were built in COOT72. ELMO1NTD was built into the cryo-EM density based on a
crystal structure of ELMO2 (PDB: 6IDX)42. All models were refined with
PHENIX75.
RHOG–ELMO2RBD crystal structure determination. Initial crystal screens for the
RHOG and ELMO2RBD complex (1:1 molar ratio) were performed by sitting-drop
vapour diffusion at 22 °C. After 2 days, microcrystals were obtained in 0.1 M CHES
pH 9.5 and 1.0 M sodium citrate. These crystallization conditions were optimized
by the hanging-drop vapour diffusion method at 22 °C. Suitable crystals of native
and selenium-methionine-derivatized versions were grown in 0.1 M CHES pH 8.8
and 0.95 M sodium citrate. For data collection, crystals were frozen in liquid
nitrogen with 3.5 M sodium citrate as a cryoprotectant. X-ray data were collected at
McGill Chemistry Characterization Facility of McGill University (Montreal,
Canada) using a Bruker D8 Venture single crystal X-ray diffractometer, wavelength
was 1.3417 Å, temp 100 K. Raw data were indexed, integrated, and scaled using
Proteum software. Crystallographic statistics of data collection are provided in
Supplementary Table 4.
The structure was solved by molecular replacement using Phaser in the
PHENIX75 software package. Model building and refinement were performed
using COOT72 and PHENIX75. The structure was validated with MolProbity. The
statistics of structure refinement are provided in Supplementary Table 4.
Coordinates and structure factors of the RHOG−ELMO2 RBD complex are
deposited in the Protein Data Bank (PDB) with the accession code 6UKA.
Ramachandran statistics: 97.9 allowed, 2.1 favoured.
Isothermal titration calorimetry. RHOG interactions with ELMO2 RBD domains
were measured using a MicroCal ITC200 (Malvern). Stock solutions were diluted
into filtered and degassed 20 mM Tris-HCl (pH 7.5), 100 mM NaCl and 1 mM
DTT. Experiments were carried out at 25 °C. Wild-type or mutant ELMO2RBD
were injected into a reaction cell containing RHOG wild-type or mutants. Fifty
injections at 150 s intervals were performed. Data were fit using the Origin (version
7) software (OriginLab Corporation).
Cell culture and transfections. HEK293T (293T) and HeLa cells (both cell lines
obtained from ATCC) were cultured in DMEM, supplemented with 10% foetal
bovine serum (Gibco) and 1% Penicillin/streptomycin antibiotics (Wisent). HeLa
cells were transfected using Lipofectamine 2000 (Invitrogen) according to manu-
facturer instructions. 293T cells were transfected using the calcium phosphate
method.
GST-pulldown assays and immunoblotting. For the RAC activation assays, 293
T cells were lysed as described59. For GST-RAC1G15A pulldowns, 293T cells were
lysed using 1% NP-40 (15 mM NaCl, 50 mM Tris pH7.5, 1% Nonidet P-40, 10 mM
NaF, 1 mM Na4P2O7, 1 mM Na3VO4, 1X complete protease inhibitor) buffer and
cell lysates were cleared by centrifugation and incubated with the corresponding
GST-tagged proteins on beads for 2 h at 4 °C (GST-RAC1G15A Pulldown) or 30
min at 4 °C (GST-PAK-PBD Pulldown). Lysates and GST-fusion bound complexes,
were run on SDS-electrophoresis acrylamide gels at 180 V and transferred on
nitrocellulose for 3 h at 4 °C at 50 V or overnight at 4 °C at 20 V. Immunoblots
were then blocked with 1% BSA and incubated with the indicated primary anti-
bodies overnight at 4 °C or room temperature. Immunoblots are then washed with
0.01% TBST three times and incubated with the corresponding secondary antibody
for 30 min at room temperature. Protein signals were revealed via ClarityTM
western ECL substrate (Biorad). Antibodies used: anti-Myc (Santa Cruz – SC40)
dilution factor: 2,000; anti-RAC1 (EMD - Millipore 05389), dilution factor: 3,000;
anti-FLAG (Sigma - A8592), dilution factor: 10,000. RAC activation and
DOCK2–RAC1 binding levels were quantified by densitometry analysis using the
ImageJ software program.
Boyden migration and invasion assay. Boyden assays were performed using 8 µm
pores Boyden Chambers (24-well, Costar). For the invasion assays, the upper
chamber was coated with 6 µL of Matrigel (BD Biosciences) dissolved in 100 µL of
DMEM. HeLa cells were detached and washed with DMEM 0.1% BSA. In total,
100,000 cells were seeded in the top chamber and allowed to migrate for 6 h
(migration) or 24 h (invasion) toward the bottom chamber containing 10% FBS.
Upper and lower chambers were then washed with 1x PBS and cells on the bottom
side of the chamber were fixed with 4% PFA. Cells in the upper chambers were
removed using cotton swabs and the membrane was mounted on a glass slide using
SlowFade Gold reagent (Invitrogen). The average number of migrating cells in 10
independent 20× microscope fields were evaluated, and each experiment was
performed in triplicate.
Time-lapse cell imaging. HeLa cells plated on fibronectin-coated plates (1000
cells/well in a 12-well plate) were transfected with 1 μg Myc-hELMO1/Myc-hEL-
MO1ΔNTD, 3 μg Flag-DOCK2/Flag-DOCK2YYS/EEE and 0.5 μg GFP-CRKII. Then
48 h later, cells were imaged using Time-lapse microscopy at 10 min intervals for
6 h (Speed tracking) or 24 h (for wound healing), using phase contrast brightfield.
Videos and images were obtained using Velocity and analysed via Image J software
for their speed and distance measurements.
Reporting summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.
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Data availability
EM maps are deposited in the Electron Microscopy Data Bank under accession codes: 10498
(DOCK2−ELMO1−RAC1 ternary complex, open conformation), 10497 (DOCK2− ELMO1
binary complex, closed conformation). Protein coordinates are deposited in the Protein Data
Bank under accession codes: 6TGC (DOCK2−ELMO1−RAC1 ternary complex, open
conformation), 6TGB (DOCK2−ELMO1−RAC1 ternary complex, open conformation) and
6UKA (ELMO2RBD−RHOG). Plasmids and cell lines that were generated for and used in this
study are available upon request from the authors. Source data are provided with this paper.
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